Real-world outcomes and safety of inetetamab plus pyrotinib and chemotherapy in HER2-positive metastatic breast cancer: A multicenter retrospective study

Fan Wu, Cailing Lin, Zhiwu Lin, Qingmo Yang, Xiuping Wu, Biyin Chen, Nani Li, Ruxue Zhang, Xiufeng Wu, Weiwei Huang, Xinhua Chen, Yi Hong, Kan Chen, Jian Liu, Department of Medical Oncology, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital, Fujian Key Laboratory of Translational Cancer Medicine, Shengli Clinical Medical College of Fujian Medical University, Department of Breast Surgery, Fujian Provincial Hospital, Fuzhou University Affiliated Provincial Hospital, Department of Breast Surgery, The First Affiliated Hospital of Xiamen University, Department of Breast Surgery, Zhangzhou Zhengxing Hospital, Department of Medical Oncology, The Third Affiliated People, s Hospital of Fujian University of Traditional Chinese Medicine, Department of Breast Surgery, Clinical Oncology School of Fujian Medical University, Fujian Cancer Hospital

Therapeutic Advances in Medical Oncology

Published online on August 12, 2026

Abstract

Therapeutic Advances in Medical Oncology, Volume 18, January-December 2026.
BackgroundInetetamab and pyrotinib have shown promising activity in HER2-positive metastatic breast cancer (MBC). However, real-world data on their combination with chemotherapy (IPyC) across different treatment lines remain limited.ObjectivesThis ...